Abstract
A prospective (Part I) and a retrospective (Part II) study were used to determine the safety and efficacy of corticosteroids in the treatment of septic shock. In Part I, 172 consecutive patients in septic shock admitted over an 8-year period were treated with either steroid or saline: 43 received dexamethasone (DMP), 43 received methylprednisolone (MPS), and 86 received saline. The study was double-blind and randomized, and the three groups were compared for age, severity of shock, presence of underlying disease, and year of study. In the 86 saline-treated patients, the mortality rate was 38.4% (33/86); in the steroid-treated patients, it was 10.4% (9/86). With MPS the mortality rate was 11.6% (5/43), and with DMP it was 9.3% (4/43). Thus, overall mortality was significantly less in the steroid-treated group than in the control group. Further, there was no significant difference in mortality rate between the DMP- and the MPS-treated patients. In Part II, 328 patients were studied retrospectively. One-hundred sixty were treated without steroid, and 168 were treated with either DMP or MPS. Again, the two groups of patients were compared for severity of shock, underlying disease, age, and year of study. Mortality among patients treated without steroid was 42.5% (68/160) and among patients treated with steroid was 14% (24/168); there was no significant difference in mortality rate between DMP- and MPS-treated patients. In Parts I and II combined, complications occurred in 6% of steroid-treated patients with no significant difference between DMP- and MPS-treated groups.
Keywords
Adrenal Cortex Hormones--complications
Adrenal Cortex Hormones--therapeutic use
Age Distribution
Age Factors
Biology
Bleeding
Demographic Factors
Diabetes Mellitus
Endocrine System
Heart Diseases
Hormones
Mortality--statistics
Physiology
Population
Population Characteristics
Population Dynamics
Prospective Studies
Research Methodology
Retrospective Studies
Sex Distribution
Studies
MeSH Terms
Adrenal Cortex Hormones/adverse effects,therapeutic use
Adult
Aged
Bacterial Infections/drug therapy
Chicago
Clinical Trials as Topic
Dexamethasone/therapeutic use
Female
Humans
Male
Methylprednisolone/therapeutic use
Middle Aged
Prospective Studies
Retrospective Studies
Sepsis/complications
Shock, Septic/drug therapy
Chemicals
Adrenal Cortex Hormones
Dexamethasone
Methylprednisolone
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Schumer W
Other Abstracts
eng
A 2-part study, prospective and retrospective, was conducted to determine the safety and efficacy of corticosteroids in the treatment of septic shock. In part 1, 172 consecutive patients in septic shock admitted over an 8-year period were treated with either steroid or saline: 43 received (DMP) dexamethasone
43 received (MPS) methylprednisolone
and 86 received saline. The study was double-blind and randomized, and the 3 groups were compared for age, severity of shock, presence of underlying disease, and year of study. In the 86 saline-treated patients, the mortality rate was 38.4% (33/86)
in the steroid-treated patients, it was 10.4% (9/86). With MPS the mortality rate was 11.6% (5/43), and with DMP it was 9.3 (4/43). Thus, overall mortality was significantly less in the steroid-treated group than in the control group. Further, there was no significant difference in mortality rate between those treated with DMP and MPS. In part 2, 328 patients were studied retrospectively. 168 were treated without steroid, and 168 were treated with either DMP or MPS. Again, the 2 groups of patients were compared for severity of shock, underlying disease, age, and year of study. Mortality among patients treated without steroids was 42.5% (68/160) and among patients treated with steroids was 14% (24/168). There was no significant difference in mortality rate between DMP- and MPS-treated patients. In parts 1 and 2 combined, complications occurred in 6% of steroid-treated patients with no significant difference between DMP- and MPS-treated patients.
References (11)
11 references, click to expand
-
Glucocorticoid and antibiotic effect on experimental gram-negative bacteremic shock.
Arch Surg. 1975 Aug;110(8):1012-5
PMID: 1100013
-
The impairment of glucogenesis by gram negative infection.
Metabolism. 1968 Jul;17(7):606-11
PMID: 4297876
-
Clinical trial design in studies of corticosteroids for bacterial infections.
Ann Intern Med. 1974 Jul;81(1):36-42
PMID: 4366291
-
Effects of E. coli lipopolysaccharide B treatment of rats on gluconeogenesis. In: Energy metabolism in trauma.
Ciba Found Symp. 1970;:145-54
PMID: 4943823
-
PHYSIOLOGY AND THERAPY OF BACTEREMIC SHOCK. EXPERIMENTAL AND CLINICAL OBSERVATIONS.
Am J Cardiol. 1963 Nov;12:599-613
PMID: 14075985
-
Complement in endotoxin shock: effect of complement depletion on the early hypotensive phase.
Infect Immun. 1970 Jul;2(1):38-41
PMID: 16557796
-
Glucocorticoid effect on hepatic carbohydrate metabolism in the endotoxin-shocked monkey.
Ann Surg. 1976 Apr;183(4):345-54
PMID: 817678
-
Glucocorticoid therapy in sepsis/shock caused by gram-negative microorganisms.
J Am Geriatr Soc. 1975 Nov;23(11):493-502
PMID: 1176749
-
Infections due to gram-negative organisms: an analysis of 860 patients with bacteremia at the University of Minnesota Medical Center, 1958-1966.
Medicine (Baltimore). 1969 Jul;48(4):307-32
PMID: 4897133
-
Septic shock: clinical, physiological, and pathological survey of 244 patients.
Ann Surg. 1971 May;173(5):657-66
PMID: 5091573
-
Studies on hemorrhagic and endotoxin shock in relation to vasomotor changes and endogenous circulating epinephrine, norepinephrine and serotonin.
Ann Surg. 1961 Oct;154:611-28
PMID: 14493963